NCT05478525View on ClinicalTrials.gov

A Study Evaluating the Safety, Tolerability, and Pharmacodynamic Effects of GLY-200 in Type 2 Diabetic Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

August 3, 2022

Primary Completion Date

March 14, 2023

Study Completion Date

March 14, 2023

Conditions
Type 2 Diabetes
Interventions
DRUG

GLY-200

0.5 g GLY-200 (1 x 0.5 g capsule) BID for 14 days (n=12)

DRUG

GLY-200

1.0 g GLY-200 (2 x 0.5 g capsules) BID for 14 days (n=12)

DRUG

GLY-200

2.0 g GLY-200 (4 x 0.5 g capsules) BID for 14 days (n=12)

DRUG

Placebo

1 placebo capsule BID for 14 days (n=4)

DRUG

Placebo

2 placebo capsules BID for 14 days (n=4)

DRUG

Placebo

4 placebo capsules BID for 14 days (n=4)

Trial Locations (1)

91911

ProSciento, Inc., Chula Vista

All Listed Sponsors
lead

Glyscend, Inc.

INDUSTRY